Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List
20 Setembro 2023 - 8:59AM
Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research
industry-leading Metasite™, today announced that its Chief Delivery
Officer, Darcy Forman, has been honored with a coveted spot on the
prestigious PharmaVoice 100 list. This recognition not only
underscores Darcy's leadership, it highlights the industry-wide
impact of Science 37 and its positive contributions to patients,
community providers, CROs, and clinical trial sponsors.
"Darcy's inclusion in the PharmaVoice 100 list is a
well-deserved recognition of her exceptional leadership and
unwavering commitment to our mission," says David Coman, Chief
Executive Officer at Science 37. “Her relentless drive to innovate
and dedication to improving clinical trial access is an inspiration
to all. We are proud of Darcy's achievements and look forward to
the continued impact she will deliver on behalf of Science 37,
benefiting patients and sponsors alike.”
"I'm proud of the advances our organization has made in
increasing clinical trial access,” said Darcy Forman. “This
acknowledgment underscores Science 37's mission to accelerate
clinical research by enabling universal trial access for patients.
I am honored to be acknowledged by PharmaVoice and share this award
with our entire team of dedicated leaders and forward-thinking
customers who work to enhance participant experience, improve
access, and increase diversity and real-world representation in
clinical research.”
In just over three years at Science 37, Darcy Forman has played
a pivotal role in propelling the organization to new heights.
Darcy's leadership extends across various domains, from patient
recruitment and engagement, to clinical operations, global provider
networks, and oversight of mobile nursing. Darcy has effectively
built an entire organization within Science 37, empowering the
company to scale the Metasite.
Science 37's unique approach is the Metasite, a virtual site
that enables patients to participate in clinical research from the
comfort of their homes. In collaboration with Science 37's
industry-leading telemedicine investigators and medical affairs
experts, Darcy’s team has achieved groundbreaking advancements in
decentralized clinical trial conduct. This includes the delivery of
in-home spirometry for a top pharmaceutical company's asthma study,
ensuring the highest data quality standards; the launch of a Phase
III, pivotal cardiology study, that surpassed trial startup times;
a breast cancer trial, with flawless execution of more than 2,000
home nursing visits, and more. With patient recruitment and
retention rates that surpass industry standards, Science 37’s
delivery team under Darcy’s leadership continues to transform
clinical trial conduct.
About Science 37Science 37 Holdings, Inc.’s
(Nasdaq: SNCE) mission is to accelerate clinical research by
enabling universal trial access for patients. Through our Metasite™
we reach an expanded population beyond the traditional site,
delivering on our goal of clinical research that works for
everyone—with greater patient diversity. Patients gain the
flexibility to participate from the comfort of their own homes, at
their local community provider, or at a traditional site when
needed. Our Metasite is powered by a proprietary technology
platform with in-house medical and operational experts that drive
uniform study orchestration, enabling greater compliance and
high-quality data. To learn more, visit www.science37.com, or email
science37@science37.com.
About PharmaVoicePharmaVoice is a leading
industry publication operated by Industry Dive. Our stories deliver
the most important voices and ideas in the life sciences to
industry leaders.
About Industry DiveIndustry Dive, an Informa
business, is a leading business journalism company. Over 14 million
decision-makers across 20+ competitive industries rely on our
exclusive insight and analysis delivered through more than 30
publications.
Cautionary Note Regarding Forward-Looking
Statements This press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37 and the markets in which it operates, and
Science 37’s anticipated growth and profitability. These
forward-looking statements generally are identified by the words
“believe,” “can,” “could”, “seek”, “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,”
“will be,” “will continue,” “will likely result” and similar
expressions. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to: (i)
the ability to maintain the listing of Science 37’s securities on
The Nasdaq Stock Market LLC, (ii) volatility in the price of
Science 37’s securities due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Science 37 operates, variations in performance across competitors,
changes in laws and regulations affecting Science 37’s business,
changes in its capital structure, and general economic and
financial market conditions, including fluctuations in currency
exchange rates, economic instability, and inflationary conditions
(iii) the ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional opportunities,
(iv) the risk that Science 37 may never achieve or sustain
profitability, (v) the risk that Science 37 will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all, (vi) failure to realize
anticipated cost savings, and (vii) risks related to general
economic and financial market conditions. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” section of Science 37’s Annual Report on Form
10-K for the fiscal year ended December 31, 2022 filed with the
U.S. Securities and Exchange Commission (the “SEC”) on March 6,
2023 and in the other documents filed by Science 37 from time to
time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Science 37
assumes no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as required by law. Science 37
does not give any assurance that Science 37 will achieve its
expectations.
MEDIA INQUIRIES:Grazia MohrenScience
37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Science 37 (NASDAQ:SNCE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024